Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adagene Inc ADAG

Healthcare Biotechnology
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced... see more

Recent & Breaking News (NDAQ:ADAG)

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

GlobeNewswire November 21, 2022

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody(TM), ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

GlobeNewswire November 10, 2022

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody(TM), ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November

GlobeNewswire October 11, 2022

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

GlobeNewswire September 10, 2022

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

GlobeNewswire August 30, 2022

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

GlobeNewswire June 29, 2022

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

GlobeNewswire May 26, 2022

Adagene to Participate in Investor Conferences in May and June

GlobeNewswire May 12, 2022

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

GlobeNewswire April 8, 2022

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2022

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

GlobeNewswire March 16, 2022

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 8, 2022

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

GlobeNewswire March 2, 2022

Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

GlobeNewswire February 8, 2022

Adagene Announces Board and Management Appointments to Support Pipeline Growth

GlobeNewswire February 2, 2022

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

GlobeNewswire January 27, 2022

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

GlobeNewswire January 19, 2022

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

GlobeNewswire January 13, 2022

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

GlobeNewswire December 22, 2021

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody(TM)

GlobeNewswire December 13, 2021